Metabolic risk factors in first-episode schizophrenia: Baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial

International Journal of Neuropsychopharmacology

Volumn 16, Issue 5, 2013, Pages 987-995

  Fleischhacker, W Wolfgang ^a   Siu, Cynthia O ^b   Bodén, Robert ^c   Pappadopulos, Elizabeth ^d   Karayal, Onur N ^d   Kahn, René S ^e  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Data Power Inc   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d PFIZER INC   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotic; antipsychotic naive; first episode; metabolic syndrome; schizophrenia

Indexed keywords

AMISULPRIDE; CHOLESTEROL; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; OLANZAPINE; QUETIAPINE; TRIACYLGLYCEROL; ZIPRASIDONE;

ABDOMINAL OBESITY; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OPEN STUDY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; CARDIOVASCULAR DISEASES; EUROPE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; METABOLIC DISEASES; OBESITY, ABDOMINAL; RISK FACTORS; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 84877996294     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001241     Document Type: Article

References (46)

1. Balkau B, Vernay M, Mhamdi L, Novak M, et al., (2003) The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome: the French D. E. S.I. R. study. Diabetes Metab 29:526-532.
2. Bertelsen M, Jeppesen P, Petersen L, Thorup A, et al., (2009) Course of illness in a sample of 265 patients with first-episode psychosis-five year follow-up of the Danish OPUS trials. Schizophr Res 107:173-178.
3. Bobes J, Arango C, Aranda P, Carmena R, et al., (2007) Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res 90:162-173.
4. Bobes J, Arango C, Rejas J, for the CLAMORS Study Collaborative Group (2010) Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 71:280-286.
5. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, et al., (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 302:1765-1773.
6. De Hert M, Detraux J, van Winkel R, Yu W, et al., (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114-126.
7. De Hert M, van Eyck D, De Nayer A (2006) Metabolic abnormalities associated with second generation antipsychotics: facts or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21(Suppl. 2):S11-S15.
8. De Hert MD, Schreurs V, Sweers K, Van Eyck D, et al., (2008) Typical and atypical antipsychotics differentially affect longterm incidence rates of the metabolic syndrome in firstepisode patients with schizophrenia: a retrospective chart review. Schizophr Res 100:295-303.
9. de Kroon MLA, Renders CM, Kupiers ECC, van Wouwe JP, et al., (2008) Identifying metabolic syndrome without blood tests in young adults-the Terneuzen birth cohort. Eur J Public Health 18:656-660.
10. Despres JP, Lemieus I (2006) Abdominal obesity and metabolic syndrome. Nature 444:881-887.
11. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415-1428.
12. Ervin RB (2009) Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity and body mass index. Natl Health Stat Rep 13:1-7.
13. Fitzmaurice GM, Laird NM, Ware JM (2004) Applied longitudinal analysis. Hoboken. NJ: John Wiley & Sons, Inc.
14. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, et al., (2008) Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 69:514-519.
15. Fleischhacker WW, Keet IP, Kahn RS (2005) The European first episode schizophrenia trial (EUFEST): rationale and design of the trial. Schizophr Res 7:147-156.
16. Ford ES, Giles WH, Dietz WH (2002) Prevalence of metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. J Am Med Assoc 287:356-359.
17. Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK (2010) Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep 10:209-216.
18. Johnsen E, Gjestad R, Kroken RA, Mellesdal L et al., (2011) Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study. Nord J Psychiatry 65:192-202.
19. Johnson WD, Kroon JJM, Greenway FL, Bouchard C, et al., (2009) Prevalence of risk factors for metabolic syndromes in adolescents. Arch Pediatr Med 163:371-377.
20. Kahn R (2008) Metabolic syndrome-what is the clinical usefulness? Lancet 371:1892-1893.
21. Kahn RS, Fleischhacker WW, Boter H, Davidson M, et al. for the EUFEST study group (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 371:1085-1097.
22. Kulina EV, Yoon PW, Keenan NL (2010) Prevalence of coronary heart disease risk factors and screening for high cholesterol levels among young adults, United States, 1999-2006. Ann Fam Med 8:327-333.
23. Kurzthaler I, Fleischhacker WW (2001) The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 62(Suppl. 7):32-37.
24. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, et al. for the Clinical Antipsychotic Trials of Intervention Effectiveness Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 35:1209-1223.
25. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, et al., (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32.
26. Matthews DR, Hosker JP, Rudenski AS, et al., (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419.
27. Mattsson N, Ronnemaa T, Juonala M, Viikari JSA, et al., (2008) Arterial structure and function in young adults with the metabolic syndrome: the Cardiovascular Risk in Young Finns Study. Eur Heart J 29:784-791.
28. Meyer JM, Nesrallah HA, McEvoy Goff DC, et al., (2005) The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 80:9-18.
29. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, et al., (2011) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-A systematic review and meta-analysis. Schizophr Bull. Published online: 29 December 2011. doi :10.1093/schbul/sbr148.
30. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M (2012a) Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull Published online: 27 August 2011. doi:10.1093/schbul/sbs082.
31. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, et al., (2012b) Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 42:125-147.
32. Mozumdar A, Liguori G (2011) Persistent increase of prevalence of metabolic syndrome among us adults: NHANES III to NHANES 1999-2006. Diabetes Care 34:216-219.
33. Newcomer JW, Haupt DW (2006) The metabolic effects of antipsychotic medications. Can J Psychiatry 59:337-345.
34. Newcomer JW, Hennekens CH (2007) Severe mental illness and risk of cardiovascular disease. J Am Med Assoc 298:1794-1796.
35. Nielsen J, Skadhede S, Correll CU (2010) Antipsychotics associated with the development of type 2 diabetes in antipsychotic-näive schizophrenia patients. Neuropsychopharmacology 35:1997-2004.
36. Patel JK, Buckley PF, Woolson S, Hamer RM, et al., (2009) Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 111:9-16.
37. Potkin SG, Siu CO (2009) Dropouts and missing data in psychiatric clinical trials. Am J Psychiatry 166:1295.
38. Reaven GM (2005) The metabolic syndrome: requiescat in pace. Clin Chem 51:931-938.
39. Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123-1131.
40. Saddichha S, Manjunatha N, Ameen S, Akhtar S (2008) Metabolic syndrome in first-episode schizophrenia-a randomized, double-blind controlled, short-term prospective study. Schizophr Res 101:266-272.
41. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, et al., (1998) The mini-international neuropsychiatric interview (M. I. N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl. 20):22-33.
42. Stamler J, Daviglus ML, Garside DB, Dyer AR, et al., (2000) Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. J Am Med Assoc 284:311-318.
43. Tschoner A, Engl J, Laimer M, Kaser S, et al., (2007) Metabolic side effects of antipsychotic medication. Int J Clin Pract 18:1356-1370.
44. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, et al., (2003) Insulin sensitivity, insulin secretion and abdominal fat: the insulin resistance atherosclerosis study (IRAS) family study. Diabetes 52:2490-2496.
45. Willett JB, Singer JD, Martin NC (1998) The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations. Dev Psychopathol 10:395-426.
46. WHO (2009) Global Health Risks: Mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization.